Brian Andrew Jonas, Mohammad Bukari, Timothy Ferng, Deepa Jeyakumar, Caspian Oliai, Tiffany N. Tanaka, Chiung-Yu Huang, Francisco Socola. "A phase 2 study of olutasidenib in combination with azacitidine followed by olutasidenib maintenance after venetoclax plus a hypomethylating agent regimen for IDH1 -mutated acute myeloid leukemia (University of California Hematologic Malignancies Consortium Study 2441).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.tps6603